

## MATERIALS LICENSE

Amendment No. 10

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. Parkview Hospital, Osteopathic

2. 1920 Parkwood Avenue  
Toledo, OH 43624In accordance with application attached  
to letter dated April 29, 19853. License number 34-13273-01 is amended in  
its entirety to read as follows:

4. Expiration date June 30, 1990

5. Docket or  
Reference No. 030-028576. Byproduct, source, and/or  
special nuclear material7. Chemical and/or physical  
form8. Maximum amount that licensee  
may possess at any one time  
under this licenseA. Any byproduct material  
listed in Groups I  
and II of Schedule A,  
Section 35.100 of  
10 CFR 35A. Any radiopharmaceutical  
listed in Groups I  
and II of Schedule A,  
Section 35.100 of  
10 CFR 35A. As necessary for  
uses authorized  
in Subitem 9.AB. Any byproduct material  
listed in Group III of  
Schedule A, Section  
35.100 of 10 CFR 35B. Any form listed in  
Group III of Schedule A,  
Section 35.100 of  
10 CFR 35B. 2 curies  
of each byproduct  
material authorized  
in Subitem 6.B

C. Xenon-133

C. Gas or gas in solution  
that is the subject  
of an active (i.e., not  
withdrawn or terminated)  
"New Drug Application"  
(NDA) approved by FDA or  
an active (i.e., not  
withdrawn, terminated  
or on "clinical hold")  
"Notice of Claimed  
Investigational Exemption  
for a New Drug" (IND)  
that has been accepted  
by FDA

C. 200 millicuries

B506060795 B50517  
REG3 LIC30  
34-13273-01 PDR

11 COPY

2  
me30  
48 5/1/11

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

34-13273-01

Docket or Reference number

030-02857

Amendment No. 10

6. Byproduct, source,  
and/or special nuclear  
material

7. Chemical and/or  
physical form

8. Maximum amount that  
licensee may possess  
at any one time  
under this license

D. Iodine-131

D. Any iodide that has  
been manufactured, labeled,  
packaged, and distributed  
in accordance with a  
specific license issued  
pursuant to Section 32.72  
of 10 CFR Part 32 or a  
specific license issued to  
a manufacturer by an  
Agreement State pursuant to  
equivalent State regulations

D. 200 millicuries

E. Any byproduct material  
listed in Section  
31.11(a) of 10 CFR 31

E. Prepackaged kits

E. 3 millicuries  
of each byproduct  
material authorized  
in Subitem 6.E

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Blood flow studies. Pulmonary function studies.

D. For treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

E. In vitro studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1920 Parkwood Avenue, Toledo, Ohio.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

34-13273-01

Docket or Reference number

030-02857

Amendment No. 10

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Gilbert Sullivan Bucholz, D.O.

Groups I, II and III  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction and thyroid carcinoma  
Xenon-133  
In vitro studies

James Bradley Beard, D.O.

Groups I, II and III  
Xenon-133  
In vitro studies

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
- (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
15. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.
16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
  - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
  - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

COPY



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

34-13273-01

Docket or Reference number

030-02857

Amendment No. 10

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application attached to letter dated April 29, 1985 and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date May 17, 1985

Original Signed  
By James Mullauer  
Materials Licensing Section, Region III

COPY